Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors-Reference-Cited by-同舟云学术

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors

Published:2020-08-27 Issue:12 Volume:28 Page:6119-6128
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Choi Jennifer,Anderson Ronald,Blidner Ada,Cooksley Tim,Dougan Michael,Glezerman Ilya,Ginex Pamela,Girotra Monica,Gupta Dipti,Johnson Douglas,Shannon Vickie R.,Suarez-Almazor Maria,Rapoport Bernardo L.^ORCID,Lacouture Mario E.

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00520-020-05706-4.pdf

Reference45 articles.

1. Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciuc C, Eggermont AM, Soria JC, Mateus C, Robert C (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13(8):473–486. https://doi.org/10.1038/nrclinonc.2016.58

2. Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5(1):95. https://doi.org/10.1186/s40425-017-0300-z

3. Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB (2017) Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 8:49. https://doi.org/10.3389/fphar.2017.00049

4. Hassel JC, Heinzerling L, Aberle J, Bähr O, Eigentler TK, Grimm MO, Grünwald V, Leipe J, Reinmuth N, Tietze JK, Trojan J, Zimmer L, Gutzmer R (2017) Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treat Rev 57:36–49. https://doi.org/10.1016/j.ctrv.2017.05.003

5. Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K, ESMO Guidelines Committee (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv119–iv142. https://doi.org/10.1093/annonc/mdx225

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improved Dermatologist, Patient, and Oncologist Collaboration Needed During Cancer Drug Development;JAMA Dermatology;2024-06-01

2. Case report: Envafolimab causes local skin necrosis;Frontiers in Immunology;2024-03-22

3. Network pharmacology and molecular docking to explore the mechanism of a clinical proved recipe for external use of clearing heat and removing dampness in the treatment of immune-related cutaneous adverse events;Medicine;2024-03-15

4. Early Recognition and Management of Side Effects Related to Systemic Anticancer Therapy for Advanced Breast Cancer;Seminars in Oncology Nursing;2024-02

5. Experiences of immune-related skin toxicity: a qualitative study among patients with cancer;2024-02-01